Public Health Impact of Introducing a Pentavalent Vaccine Against Invasive Meningococcal Disease in the United States
A routinely recommended two-dose pentavalent vaccine, with doses administered 6 months apart at 16 years of age, alongside the routinely recommended MenACWY vaccine at 11 years of age, would improve the PHI and benefits of IMD vaccination to society.
Authors
- Hiral Shah (ORCID: https://orcid.org/0000-0003-0204-451X)
- Katherine A. Hicks (ORCID: https://orcid.org/0000-0002-1058-3401)
- Justin Carrico (ORCID: https://orcid.org/0000-0002-4659-9309)
- Oscar Herrera-Restrepo (ORCID: https://orcid.org/0000-0001-8193-999X)
- Mei Grace (ORCID: https://orcid.org/0009-0008-3862-8203)
- Elise J. Kuylen (ORCID: https://orcid.org/0000-0002-3528-5507)
- Shahina Begum (ORCID: https://orcid.org/0000-0002-3521-8865)
- Woo-Yun Sohn (ORCID: https://orcid.org/0000-0002-4034-4735)
- Diana E. Clements (ORCID: https://orcid.org/0000-0002-2410-8951)
- James E. Graham (ORCID: https://orcid.org/0000-0002-3227-5928)
- Cynthia Burman (ORCID: https://orcid.org/0009-0000-2860-1500)
- Zeki Kocaata (ORCID: https://orcid.org/0000-0002-5231-3389)
- Ginita Jutlla (ORCID: https://orcid.org/0000-0001-6065-8574)
Institutions
- GlaxoSmithKline (Belgium) (BE)
- GlaxoSmithKline (United States) (US)
- RTI Health Solutions (US)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- GlaxoSmithKline (Germany) (DE)
Publication Details
- Journal
- PharmacoEconomics
- Published
- 2024-11-25
- DOI
- https://doi.org/10.1007/s40273-024-01439-y
- Citations
- 3
- Primary Topic
- Bacterial Infections and Vaccines
- Type
- article
- Field-Weighted Citation Impact
- 1.03